Clinical TrialJun 13, 2026, 04:01 PM
Ascendis Pharma TransCon PTH Phase 3 data shows 86% response rate
AI Summary
Ascendis Pharma announced positive Week 182 data from its completed Phase 3 PaTHway Trial for TransCon PTH in adults with hypoparathyroidism. The long-term treatment demonstrated sustained efficacy and safety over three and a half years, with 86% of patients achieving the multi-component endpoint and 89% completing the trial. TransCon PTH replicated endogenous PTH actions, improving quality of life, normalizing key biochemistries, and enhancing kidney function while enabling independence from conventional therapy.
Key Highlights
- 86% of patients were responders for the multi-component endpoint.
- 89% of patients completed the three-and-a-half-year trial.
- 100% of patients achieved independence from active vitamin D.
- 96% of patients achieved independence from therapeutic doses of calcium.
- Mean eGFR increased by 11.0 mL/min/1.73 m2 from baseline, maintained at 80.2 mL/min/1.73 m2.
- Mean 24-hour urine calcium normalized within 26 weeks and remained normal.
- No new safety signals identified, and no patients developed anti-PTH antibodies.
Price Impact
More from ASND